louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03886233: Treatment Outcome of Uveitis in Autoimmune Diseases
Official title: Treatment Outcome of Uveitis in Autoimmune Diseases
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Autoimmune Uveitis
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2019-03-22
Enrollment: 1
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The study will include uveitis caused by autoimmune diseases. Uveitis can be anterior (including iritis or iridocyclitis). Intermediate uveitis or vitritis involves the vitreous cavity and may involve the pars plana. Finally, posterior uveitis is divided in three types: choroiditis, retinochoroiditis, and chorioretinitis. In diffuse involvement or when uveitis affects many areas, it is described as panuveitis.

Brief summary: reviewing the outcomes of patients with uveitis caused by autoimmune diseases treated at Assiut University Hospital at the Ophthalmology and Rheumatology and Rehabilitation Departments.

Detailed description: Autoimmune uveitis (AU) is an inflammation of the uvea caused by either an autoimmune reaction to self-antigens or an innate inflammatory reaction secondary to an external stimulus. Corticosteroids are considered the gold standard in management of acute AU, but it is necessary to combine them with other immunosuppressive drugs. Finally, biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab) are also showing very promising results. Follow-up visits of subjects with uveitis must be frequent and focused on monitoring the recurrence of acute outbreaks, , if any. They should be aimed to determine the evolution of inflammatory signs until their complete resolution, thus ensuring the least possible consequences. After the initial phase of the treatment, the duration of use of the maintenance medication is directly related to the diagnosis, treatment and control of the underlying disease. This will help to determine if a patient is badly controlled and requires a more aggressive therapeutic plan. Also, a complete physical exam must be done each time the patient sees to the physician in order to monitor ophthalmological complications or development of adverse effects secondary to the treatment.

Eligibility criteria: Inclusion Criteria:

* Uveitis with clinical features of autoimmune disease;

Exclusion Criteria:

* Other infectious and non-infectious uveitic etiologies that may mimic the given clinical presentation of autoimmune uveitis;

Primary outcomes:
measure: determination the best method for treatment of autoimmune uveitis
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Assiut University
name: Hasan L Fahmy, Prof.
role: STUDY_CHAIR
affiliation: Assiut University
name: Mohamed G Saleh, lecturer
role: STUDY_DIRECTOR
References:
Clinical trial NCT00767533: Immunobiology of Cancer
Official title: Immunobiology of Cancer
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Neoplasms
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2008-10-07
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants who have cancer or participants who do not have cancer and/or an autoimmune disorder and are age 18 or over.

Brief summary: To learn whether or not an Interferon defect in cell signaling, recently discovered in immune cells from melanoma patients as well as breast cancer patients, is common to all cancers.

Detailed description: BACKGROUND

We have previously demonstrated that tumor-specific T cells could be identified in \>50% of patients with metastatic melanoma and these cells appeared to be rendered anergic in vivo \[Nature Medicine 5:677, 1999\]. Recently we discovered that there is a signaling defect in the Interferon (IFN) pathway in immune cells from melanoma patients \[PLOS Medicine 4:897 2007\]. Interestingly, preliminary studies are showing the same defect in immune cells from breast cancer patients (unpublished). We would like to expand our research to all types of cancer to determine whether these phenomena occur in different cancer types.

OBJECTIVES

Our primary objective is to determine whether there is an IFN signaling defect in different types of cancers and to determine what is causing this defect.

The second objective is to determine whether these PBMCs are rendered anergic.

INVESTIGATIONAL PLAN

The study population will consist of patients who have been diagnosed with cancer, regardless of sex or ethnicity. Blood will be collected during the subjects regularly scheduled laboratory appointment and peripheral blood mononuclear cells (PBMCs) will be isolated for research purposes. These PBMCs will undergo studies, i.e. phosflow, qPCR, proliferation, survival, etc., to determine immune responses for T cells (CD4 and CD8), B cells (CD19), natural killer cells (CD16), and possibly monocytes (CD14).

Eligibility criteria: Inclusion Criteria:Participants who have cancer or participants who do not have cancer and/or an autoimmune disorder and are age 18 or over. Exclusion Criteria:Participants who have an autoimmune disorder and/or are under the age of 18 years.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Peter P Lee
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04117633: Laparoscopic Suture Versus Mesh Rectopexy for the Treatment of Persistent Complete Rectal Prolapse in Children
Official title: Laparoscopic Suture Versus Mesh Rectopexy for the Treatment of Persistent Complete Rectal Prolapse in Children : A Comparative Randomized Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Rectal Prolapse
Keywords: Rectal Prolapse
Laparoscopy
Mesh
Rectopexy
pediatrics
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2019-10-07
Enrollment: 64
Sex: ALL
Minimum age (years): 5
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The study included two equal groups. one group underwent laparoscopic mesh rectopexy and the other underwent suture rectopexy.
Primary purpose: SUPPORTIVE_CARE

Brief summary: Purpose: to compare Laparoscopic mesh rectopexy with laparoscopic suture rectopexy The operative time, recurrence rate, post-operative constipation, and effect on fecal incontinence, were reported and evaluated for each group Results:

Detailed description: Purpose: to compare Laparoscopic mesh rectopexy with laparoscopic suture rectopexy Patient and Methods: The prospective study was conducted at Pediatric Surgery Department, Al-Azhar university hospitals, Cairo, Egypt . The operative time, recurrence rate, post-operative constipation, and effect on fecal incontinence, were reported and evaluated for each group

Eligibility criteria: Inclusion Criteria:

Children with persistant complete Rectal Prolapse.

* Failure of conservative treatment.
* more than 2 attacks of prolapse requiring manual reduction.

Exclusion Criteria:

* Sever constipation
* Previous abdominal or pelvic surgery with extensive adhesions.
* Cases older than 12ys,
* Patients with rectal polyp

Primary outcomes:
measure: Signs of improvement
timeFrame: 12 weeks
Secondary outcomes:
measure: Signs of improvement
timeFrame: 30 weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06884033: Cinematherapy for Women With Depression and Anxiety
Official title: GINEMOTION: Cinematherapy for Women With Depression and Anxiety
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Depression Anxiety Disorder
Lead sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Sponsor class: OTHER
First posted: 2025-03-19
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Group cinematherapy program in reducing depressive and anxiety symptoms in women diagnosed with Depressive Disorders and Anxiety Disorders.

Detailed description: Cinematherapy is a creative therapeutic intervention in which a trained professional prescribes the patient to watch a film and uses the characters and themes as metaphors to promote self-exploration and change. The effectiveness of cinematherapy as a therapeutic technique has been demonstrated through its effectiveness in improving participants' self-esteem, emotional expression and understanding, and interpersonal relationships, and in reducing depressive and anxious symptoms.The cinematherapy intervention involves a targeted selection of film content and activities designed to improve the patients' mental condition.The study includes eight meetings on a monthly basis (programming of eight films lasting approximately two hours and subsequent discussion on the contents of the film shown).

Eligibility criteria: Inclusion Criteria:

* female, aged 18-75 years;
* Diagnosis of Depressive Disorders (unipolar and bipolar) and Anxiety Disorders according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5), both new onset in subjects without a previous psychiatric history, and depressive and anxious recurrences;
* Taking psychopharmacological therapy;
* Fluent knowledge of the Italian language;
* Release of a written informed consent, signed by the patient or legal representative and partner.

Exclusion Criteria:

* Diagnosis of Schizophrenia or other psychotic spectrum disorders;
* Diagnosis of neurological disorders associated with cognitive decline;
* Current abuse of alcohol and psychotropic substances, with the exception of smoking;
* Refusal to sign the informed consent to participate in the study.

Primary outcomes:
measure: Assessment of change from baseline in anxiety symptoms.
timeFrame: 8 months
measure: Assessment of change from baseline in depression symptoms.
timeFrame: 8 months
Secondary outcomes:
measure: Weight will be collected for all patients.
timeFrame: 8 months
measure: Eight will be collected for all patients.
timeFrame: 8 months
measure: Body mass index (BMI) will be collected for all patients.
timeFrame: 8 months
measure: Heart rate variability (HRV) will be collected for all patients.
timeFrame: 8 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03895333: Hearing Loss and Osteoporosis
Official title: Audiological Profiling in Postmenopausal Women With Osteoporosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hearing Loss
Osteoporosis, Postmenopausal
Keywords: Bone mineral density
Postmenopause
Lead sponsor: Kanuni Sultan Suleyman Training and Research Hospital
Sponsor class: OTHER
First posted: 2019-03-29
Enrollment: 160
Sex: FEMALE
Minimum age (years): 45
Maximum age (years): 60
Standard ages: ADULT
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Postmenopausal women who had hearing test between the ages of 45-60 formed the study group

Brief summary: To compare the audiological profiles in postmenopausal women with and without osteoporosis and to examine the pattern of hearing loss in osteoporotic patients. postmenopausal women will be separated as normal, osteopenic and osteoporotic according to bone mineral densitometry results. The evaluation of hearing test will be done in these groups and the results will be compared between the groups.


Eligibility criteria: Inclusion Criteria:

* Between 45-60 years
* postmenopausal women

Exclusion Criteria:

* Women over 60 years old,
* acute or chronic otitis media,
* ear surgery,
* use of ototoxic drugs,
* congenital hearing loss,
* previous long-term steroid use,
* malignant or benign neoplasm of the brain,
* Patients with a history of exposure to noise were excluded from the study.

Primary outcomes:
measure: hearing test results
timeFrame: 1 week
measure: bone mineral densitometry measurements
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Kanuni Sultan Süleyman Training and Research Hospital
Study officials:
References:
Clinical trial NCT05017233: Spectral CT Clinical Trial Protocol
Official title: Spectral CT Clinical Trial Protocol
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: CT Scanning
Lead sponsor: Philips (China) Investment CO., LTD
Sponsor class: INDUSTRY
Collaborators: name: Shanghai Changzheng Hospital
name: Ruijin Hospital
name: West China Hospital
First posted: 2021-08-23
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study was to evaluate the expected effectiveness, ease of operation, stability, and safety of Spectral CT

Detailed description: Under the premise of protecting subjects and ensuring the scientific nature of this study, Spectral CT was evaluated for its effectiveness, convenience, stability and safety under normal conditions by collecting clinical cases.

Eligibility criteria: Inclusion Criteria:

* Recruit volunteers (ages 18 to 75);
* Negative pregnancy tests in women of childbearing age;
* Participants who agree to participate in this clinical trial and sign the informed consent;
* Enhanced scans require laboratory tests to confirm normal renal function.

Exclusion Criteria:

* Persons who do not have full capacity for civil conduct;
* Lactating women;
* People who are not suitable for enhanced scanning with iodine contrast agent;
* Patients whom the investigator considers inappropriate to participate in this clinical trial.

Primary outcomes:
measure: Excellent and good rate of clinical imaging (score≥3）
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
measure: Common functions assessment
timeFrame: through study completion, an average of 1 year
measure: Convenience evaluation assessment
timeFrame: through study completion, an average of 1 year
measure: Machine function and stability assessment
timeFrame: through study completion, an average of 1 year
measure: Adverse events and serious adverse events
timeFrame: through study completion, an average of 1 year
Other outcomes:
Locations:
city: Chengdu
country: China
facility: West China Hospital
state: Sichuan
city: Shanghai
country: China
facility: Ruijin Hospital
city: Shanghai
country: China
facility: Shanghai Changzheng Hospital
Study officials:
affiliation: Shanghai Changzheng Hospital
name: Shiyuan Liu, Director
role: PRINCIPAL_INVESTIGATOR
affiliation: Ruijin Hospital
name: Fuhua Yan, Director
role: PRINCIPAL_INVESTIGATOR
affiliation: West China Hospital
name: Bin Song, Director
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06581133: Sleep Disruption Pattern - Epilepsy Monitoring Unit
Official title: Introducing a Structured Sleep Disruption Pattern to Provoke Earlier Seizures During Epilepsy Monitoring Unit Admissions
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Epilepsy Intractable
Keywords: epilepsy monitoring unit
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2024-09-03
Enrollment: 75
Sex: ALL
Minimum age (years): 14
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: During their epilepsy monitoring unit (EMU) admission, patients will be divided into either the alarm group or the control group. Patients in the alarm group will have an alarm system placed in their room, scheduled to sound at several timepoints during the night. This intervention will be conducted throughout the whole EMU admission. Patients in the control group will have an alarm system placed in their room, but the alarm system will not sound during any of the nights during their EMU admission.
Primary purpose: OTHER

Brief summary: Epilepsy affects millions worldwide, with 40% of patients experiencing uncontrolled seizures despite medication. Comprehensive epilepsy centers recommend continuous video-electroencephalography monitoring to define seizure type and distinguish mimickers. This process, however, is resource-intensive, with lengthy hospital stays. The investigators' recent study identified a heightened association between arousals and epileptic activity in drug-resistant focal epilepsy patients. Building on these findings, the investigators aim to explore whether disrupting sleep with an alarm system triggers earlier occurrence of seizures, potentially offering insights to reduce hospital stay durations in epilepsy monitoring units.


Eligibility criteria: Inclusion Criteria:

* Age 14 to 60 years
* EMU monitoring for presurgical evaluations
* Average 2-3 seizures per week based on pre-admission seizure diary
* Sleep as a known seizure trigger

Exclusion Criteria:

- Multiple seizures a day based on pre-admission seizure diary

Primary outcomes:
measure: Seizure frequency during EMU (epilepsy monitoring unit) stay
timeFrame: 1 month after the EMU stay (up to 9 weeks)
measure: Duration of EMU (epilepsy monitoring unit) admission
timeFrame: 1 month after the EMU stay (up to 9 weeks)
measure: Average interictal spike rates
timeFrame: 1 month after the EMU stay (up to 9 weeks)
measure: Change in sleep quality
timeFrame: Baseline (Day 1), last day of EMU stay (up to 5 weeks), 1 month after the EMU stay (up to 9 weeks)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Duke University
name: Birgit Frauscher, MD PD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05851833: A Retrospective Study of Early Postoperative Mobilization in the Recovery of Patients With Oral Head and Neck Tumors Who Underwent Flap Reconstruction
Official title: A Retrospective Study of Early Postoperative Mobilization in the Recovery of Patients With Oral Head and Neck Tumors Who Underwent Flap Reconstruction
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Length of Hospital Stay
Lead sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Sponsor class: OTHER
First posted: 2023-05-10
Enrollment: 244
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Early Mobilizationon Recovery After Major Head and Neck Surgery With Flap Reconstruction

Brief summary: All patients with head and neck cancers and osteomyelitis who underwent vascularized flap reconstruction at Shanghai Ninth People's Hospital (North Campus), Shanghai Jiao Tong University, from February 2020 to July 2021 were the object of a retrospective data collection.Depending on whether they had postoperative early mobilization, all patients were split into experimental and control groups.In the experimental group, patients were split into two groups based on the postoperative day(POD): the POD 0-1 group and the POD \>1 group.Comparison and analysis were done on the difference in hospital days and post-operative complication rates between the two groups.


Eligibility criteria: Inclusion Criteria:

1. Patients with head and neck diseases undergoing flap reconstruction and repair
2. Patients with complete data preservation and consent
3. Patients who follow medical advice during hospitalization

Exclusion Criteria:

1. Patients who survived less than 1 month after surgery
2. Patients with other tumors before surgery 3, mental patients, audio-visual impairment or uncooperative patients

Primary outcomes:
measure: Length of hospital stay after surgery
timeFrame: February 2020 to July 2021
Secondary outcomes:
measure: pulmonary infection rate
timeFrame: February 2020 to July 2021
measure: deep vein thrombosis rate
timeFrame: February 2020 to July 2021
measure: flap crisis rate
timeFrame: February 2020 to July 2021
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Ninth People's Hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT06647433: What is the Perceived Role of Risk in DOC Healthcare.
Official title: What is the Perceived Role of Risk in the Healthcare Received by People in Disorders of Consciousness (DOC)?
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Disorders of Consciousness
Keywords: Disorders of Consciousness
Decision making
Lead sponsor: University of Nottingham
Sponsor class: OTHER
Collaborators: name: Royal Hospital for Neuro-disability
First posted: 2024-10-17
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: people in a doc

Brief summary: Critical ethnography exploring how decisions are made on behalf of people in disorder of consciousness (DOC).

Prospective longitudinal case study design including observation, field interview and video reflexive ethnography.


Eligibility criteria: Inclusion Criteria:

* People in a DOC:
* Working diagnosis of being in a DOC.
* Have an appropriate family member able to act as a consultee.
* Over 18 years of age.

Family members and healthcare workers:

* conversational English.
* able to give consent.
* over 18 years of age.
* Involved in decision making on behalf of a person in a DOC

Exclusion Criteria:

Person in a Disorder of Consciousness

* Not in a DOC, diagnosis uncertain, or appears to be emerging.
* Clinically unstable or approaching the end of their life.

Primary outcomes:
measure: Meaning based themes on what influences decision making in DOC
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Nottingham
country: United Kingdom
facility: University of Nottingham
Study officials:
References: